Silver
CAS 7440-22-4
Silver (CAS 7440-22-4) is a pharmaceutical compound with 0 bioactivity targets and 16 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Silver is linked to DTXSID4024305 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SILVER | 2606543 | SU | MTHSPL |
| Silver | 2606543 | SU | MTHSPL |
| silver | 2606543 | IN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Agranulocytosis | silver | LLT | C0001824 |
| Agranulocytosis | silver | PT | C0001824 |
| Aplastic anaemia | silver | LLT | C0002874 |
| Aplastic anaemia | silver | PT | C0002874 |
| Bacterial colonisation | silver | LLT | C2747813 |
| Bacterial colonisation | silver | LLT | C2747813 |
| Bacterial disease carrier | silver | PT | C0853960 |
| Bacterial disease carrier | silver | PT | C0853960 |
| Blood disorder | silver | LLT | C0018939 |
| Blood disorder | silver | PT | C0018939 |
| Burning sensation | silver | LLT | C0085624 |
| Burning sensation | silver | PT | C0085624 |
| Burning sensation | silver | LLT | C0085624 |
| Burning sensation | silver | PT | C0085624 |
| Dermatitis | silver | PT | C0011603 |
| Dermatitis | silver | PT | C0011603 |
| Dermatitis exfoliative | silver | LLT | C0011606 |
| Dermatitis exfoliative | silver | PT | C0011606 |
| Erythema multiforme | silver | LLT | C0014742 |
| Erythema multiforme | silver | PT | C0014742 |
| Erythema multiforme | silver | PT | C0014742 |
| Erythema multiforme | silver | LLT | C0014742 |
| Erythema multiforme | silver | PT | C0014742 |
| Gastrointestinal disorder | silver | PT | C0017178 |
| Haemolytic anaemia | silver | LLT | C0002878 |
| Haemolytic anaemia | silver | PT | C0002878 |
| Hepatic necrosis | silver | LLT | C0151798 |
| Hepatic necrosis | silver | PT | C0151798 |
| Hepatitis | silver | LLT | C0019158 |
| Hepatitis | silver | PT | C0019158 |
| Hypersensitivity | silver | LLT | C0020517 |
| Hypersensitivity | silver | PT | C0020517 |
| Leukopenia | silver | LLT | C0023530 |
| Leukopenia | silver | PT | C0023530 |
| Leukopenia | silver | LLT | C0023530 |
| Leukopenia | silver | PT | C0023530 |
| Muscle contracture | silver | LLT | C0009917 |
| Muscle contracture | silver | PT | C0009917 |
| Muscle contracture | silver | LLT | C0009917 |
| Muscle contracture | silver | PT | C0009917 |
| Nephritis interstitial | silver | LLT | C0027707 |
| Nephritis interstitial | silver | LLT | C0027707 |
| Nephrosis | silver | LLT | C0027720 |
| Nephrotic syndrome | silver | PT | C0027726 |
| Partner stress | silver | PT | C1619718 |
| Partner stress | silver | PT | C1619718 |
| Rash | silver | LLT | C0015230 |
| Rash | silver | PT | C0015230 |
| Rash | silver | LLT | C0015230 |
| Rash | silver | PT | C0015230 |
| Reaction gastrointestinal | silver | LLT | C0542184 |
| Separation | silver | LLT | C0036679 |
| Separation | silver | LLT | C0036679 |
| Sepsis | silver | LLT | C0243026 |
| Sepsis | silver | PT | C0243026 |
| Sepsis | silver | LLT | C0243026 |
| Sepsis | silver | PT | C0243026 |
| Skin discolouration | silver | LLT | C0151907 |
| Skin discolouration | silver | PT | C0151907 |
| Skin discolouration | silver | LLT | C0151907 |
| Skin discolouration | silver | PT | C0151907 |
| Skin exfoliation | silver | PT | C0237849 |
| Skin exfoliation | silver | PT | C0237849 |
| Skin necrosis | silver | LLT | C0151799 |
| Skin necrosis | silver | PT | C0151799 |
| Skin necrosis | silver | LLT | C0151799 |
| Skin necrosis | silver | PT | C0151799 |
| Stevens-Johnson syndrome | silver | LLT | C0038325 |
| Stevens-Johnson syndrome | silver | PT | C0038325 |
| Thrombocytopenia | silver | LLT | C0040034 |
| Thrombocytopenia | silver | PT | C0040034 |
| Tubulointerstitial nephritis | silver | PT | C0041349 |
| Tubulointerstitial nephritis | silver | PT | C0041349 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Silver used for in pharmaceutical contexts?
Silver (CAS 7440-22-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Silver?
Silver has 16 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Accidental overdose, COVID-19, Constipation, Diarrhoea, Flatulence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Silver also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Colloidal Silver with EU status "prohibited".
What clinical phase is Silver in?
No phase 1-4 clinical development badge is rendered for Silver because the matched compound identifier rows do not contain a max-phase value.